Advertisement

LeMaitre Vascular, Inc. LMAT

Set alert

Price alert · LMAT

All alert types
81.26 USD +0.32 +0.40%

At close · Nov 2

80.44 -0.82 -1.01%

After hours · Nov 2, 4:10 PM ET

Bid
81.20 × 1
Ask
81.27 × 2
80.80 Day range 82.38
78.22 52-week range 118.01
YTD
+0.20%
1 year
-6.18%
Open
82.06
Prev close
80.94
Mkt cap
1.86B
Vol
270.71K
Avg vol
329.07K
EPS
2.85
P/E
28.51
Div yield
1.24%
More statistics
Low
80.80
High
82.38
Forward P/E
25.56
Beta
0.49
Short ratio
6.66
Inst. own
105.32%
Dividend
1.00
Ex-div date
Aug 19, 2026
Earnings
Nov 4, 2026
50-d avg
81.20
200-d avg
94.47
1y target
107.00

1M chart

Chart tools
Interval

Signals (12)
NameDateAgo
SMA: BullishNov 2, 20266 hours ago
MACD: Sell SignalNov 2, 20266 hours ago
SMA: BearishOct 30, 20263 days ago
SMA: BearishOct 30, 20263 days ago
SMA: BullishOct 29, 20264 days ago
SMA: BearishOct 28, 20265 days ago
SMA: BullishOct 19, 20262 weeks ago
SMA: BullishOct 19, 20262 weeks ago
SMA: BearishOct 16, 20262 weeks ago
SMA: BearishOct 16, 20262 weeks ago
SMA: BullishOct 12, 20263 weeks ago
SMA: BullishOct 9, 20263 weeks ago

Key statistics

Market cap
1.86B
Enterprise value
1.67B
Trailing P/E
28.51
Forward P/E
25.56
PEG ratio
2.14
Price / sales
7.08
Price / book
4.42
EPS (TTM)
2.85
Beta
0.49
Dividend yield
1.24%
Payout ratio
31.58%
Profit margin
25.02%
Revenue (TTM)
262.43M
Revenue growth
9.60%
Free cash flow
49.26M
Total cash
376.24M
Total debt
190.25M
Return on equity
16.77%
Shares outstanding
22.87M
Short % of float
9.76%
50-day average
81.20
200-day average
94.47

Analyst view

Consensus: buy

Buy
Price target (mean) 107.00 +31.7% upside
Target (low)
81.00
Target (mean)
107.00
Target (high)
132.00
Ratings (0m) 8 4 buy · 4 hold · 0 sell
  • Strong buy2
  • Buy2
  • Hold4
  • Sell0
  • Strong sell0

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 0.68625.

Earnings history

Financials — quick view

All financials
LMAT Revenue — quarterly 70.38M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
LMAT Net income — quarterly 17.05M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
LMAT EPS — quarterly 0.75
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

LMAT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 20260.686———
Aug 4, 2026Jun 30, 20260.8070.74-0.07-8.30%
May 5, 2026Mar 31, 20260.660.68+0.02+3.03%
Feb 25, 2026Dec 31, 20250.670.68+0.01+1.49%
Nov 6, 2025Sep 30, 20250.5640.62+0.06+9.93%
Aug 5, 2025Jun 30, 20250.570.60+0.03+5.26%

Upgrades / downgrades

LMAT analyst upgrades and downgrades
DateFirmActionFromTo
Aug 5, 2026Wells FargomainEqual-WeightEqual-Weight
Jun 3, 2026Barrington ResearchmainOutperformOutperform
May 6, 2026Barrington ResearchmainOutperformOutperform
May 6, 2026CitizensmainMarket OutperformMarket Outperform
May 6, 2026Wells FargomainEqual-WeightEqual-Weight
Feb 26, 2026Barrington ResearchmainOutperformOutperform

About LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
lemaitre.com

News

Your note

Sign in to keep a note on LMAT — it syncs with the Stock Master app.

Insider holders

LMAT insider holders
InsiderRelationLatest transactionDateShares held
JASINSKI LAWRENCE JDirectorConversion of Exercise of derivative securityMay 6, 20264,714
KAMKE TRENT GOfficerConversion of Exercise of derivative securityMar 10, 20266,677
LEBLANC DORIAN PAUL CPAChief Financial OfficerConversion of Exercise of derivative securityMar 9, 20262,302
LEMAITRE GEORGE WChief Executive OfficerStock GiftJun 3, 20261,463,420
O'CONNOR JOHN JAMES EDWARDDirectorConversion of Exercise of derivative securityFeb 25, 202662,827
PELLEGRINO JOSEPH P JRDirectorConversion of Exercise of derivative securityApr 21, 202615,021

Institution ownership

LMAT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.14.31%3,272,973265.96MJun 29, 2026
Conestoga Capital Advisors, LLC5.98%1,367,513111.12MJun 29, 2026
First Trust Advisors LP4.78%1,093,50288.86MJun 29, 2026
Congress Asset Management Co4.20%961,51478.13MSep 29, 2026
Vanguard Capital Management LLC4.17%953,43777.48MJun 29, 2026
Copeland Capital Management, LLC4.04%924,08175.09MSep 29, 2026

Fund ownership

LMAT fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.53%1,265,638102.85MSep 29, 2026
First TRT Exch-Trd Fd. VI-First TRT SMID Cap Rising Dividend Achievers4.64%1,061,70386.27MSep 29, 2026
Conestoga Funds-Conestoga Small Cap Fund3.80%869,01670.62MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.02%690,80656.13MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.46%563,06245.75MSep 29, 2026
Professionally Managed Portfolios-Congress Small Cap Growth Fund2.06%470,00038.19MSep 29, 2026
Advertisement